Paal Brunsvig

Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination

Gaute L. Hansen, Gustav Gaudernack, Paal Brunsvig et al. · Cancer Immunology Immunotherapy · 2015 · 49 citations · Full text

Medicine, Immunology, Oncology +17

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

Elin Aamdal, Else Marit Inderberg, Espen B. Ellingsen et al. · Frontiers in Immunology · 2021 · 42 citations · Full text

Medicine, Immunology, Oncology +17

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Espen B. Ellingsen, Elin Aamdal, Tormod Kyrre Guren et al. · Journal for ImmunoTherapy of Cancer · 2022 · 42 citations · Full text

Medicine, Immunology, Oncology +17

T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy

Jon Amund Kyte, Gustav Gaudernack, A. Faane et al. · OncoImmunology · 2016 · 20 citations · Full text

Life Sciences, Immunology, Oncology +17

ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.

Vivek Subbiah, Yung‐Jue Bang, Ulrik Lassen et al. · Journal of Clinical Oncology · 2016 · 15 citations

Veterinary Medicine, Oncology, Cancer Pharmacology +10